Clovis Oncology prices IPO at $13-$15 per share; Trial will test drug that makes brain tumors glow;

@FierceBiotech: PathoGenetix raises $7.5M in second closing of series B financing for rapid bacterial identification system. Story | Follow @FierceBiotech

@JohnCFierce: Exelixis has always had problems with study designs; source of issue with BMS. Fight the FDA, though? Shares tank. Item | Follow @JohnCFierce

@RyanMFierce: U.K. trial aims to test use of agents to make tricky brain tumors glow to aid surgical removal. Makes sense. Report | Follow @RyanMFierce 

 @MaureenFierce: Sanofi set to rev past Pfizer in pharma rankings. Article | Follow @MaureenFierce

> Boulder, CO-based Clovis Oncology, which is preparing for an IPO, has priced its shares between $13 and $15. Article

> In the U.K., researchers are kicking off a trial of a compound that will cause brain tumors to glow, making it easier for surgeons to identify and remove the growths. Sixty glioblastoma patients will participate in the study. Report

> GSK and Alnylam Pharmaceuticals have inked a deal for to use Alnylam's VaxiRNATM technology for certain GSK vaccine products, including influenza. Financial details were not disclosed. Release

> The Foundation Fighting Blindness has invested $8.25 million in 6 new gene therapy research projects that are targeted to have treatments ready for clinical trials within three years. Release

> H3 Biomedicine has named Dr. Markus Warmuth CEO, effective immediately. Release

> Women in Bio is opening a Boston chapter of the organization, its first in the Northeast. Report

Pharma News

@FiercePharma:  Dutch researchers are comparing GSK's Advair Diskus with a rival device in a study funded by $GSK. Item | Follow @FiercePharma

> Additional data sways NICE in favor of Pradaxa. Article

Biotech Research News

> Jackson Lab ready to start hiring for new genetics center. Item

> Caltech team designs a new and improved HIV antibody. Article

> Court ruling could derail ambitious stem cell program for synthetic blood. Report

> Investigators tout a new therapeutic approach to cardiovascular disease. News

Manufacturing News

> Ranking: Baxter, J&J lead green pharma companies. News

> Researchers tout big increase in heparin yield. Report

> KV Pharma, ex-CEO battle over recall responsibility. Item

> Closures a sign of Novartis minimizing production in Switzerland. Report

> Obama takes aim at drug shortages. News 

And Finally... Why Steve Jobs' magic doesn't work in medicine. Article

Suggested Articles

Two weeks after receiving a second dose of Moderna's COVID-19 jab, patients had "robust" levels of neutralizing antibodies against the…

Despite questions about eye-related side effects, GlaxoSmithKline's anti-BCMA treatment emerged from an advisory committee meeting with a 12-0 vote.

After Mallinckrodt's terlipressin beat placebo at reversing kidney failure, an FDA panel will discuss the phase 3 trial's surrogate endpoint.